Module 2 - Examining Advancements in the Understanding of CSU Pathophysiology, Translating Knowledge to Therapy
This self-study module is designed to enhance your understanding of the pathophysiology mediating the development of CSU.
Jonathan A. Bernstein, MD
Partner, Bernstein Allergy Group, Inc.
Professor of Medicine, Division of Allergy & Immunology
University of Cincinnati
Dr. Bernstein is an allergy specialist with over 35 years of experience treating patients with asthma, urticaria, angioedema, atopic and contact dermatitis, and women’s allergic health issues, such as chronic candida vulvovaginitis. Over his career, he has published over 275 peer-reviewed articles in allergy and clinical immunology and has been ranked by US News and World Report as being in the top 1% of doctors in his field. Dr. Bernstein, in previous years, additionally served as the president of the Academy of Allergy, Asthma & Immunology – a nationwide organization with a membership of over 7,000 allergy clinicians.Brian S. Kim, MD
Vice Chair of Research, Department of Dermatology
Icahn School of Medicine, Mount Sinai
Dr. Kim is a leading researcher worldwide in the study of patients with dermatological conditions involving itch. His research endeavors to elucidate the mechanisms that underlie neuroimmune interactions at the skin barrier surface. Over the course of his career, Dr. Kim has received the American Skin Association Research Achievement Award in Discovery (2020) and the American Dermatological Association Young Leadership Award (2019) and has published in internationally esteemed journals including the European Respiratory Journal, JAMA Dermatology, Cell, and the New England Journal of Medicine.1.
Describe the underlying pathophysiology of CSU, with a focus on type I and type II autoimmune mechanisms
2.
Discuss the mechanism of action, efficacy, and safety profiles of novel treatments for CSU, namely Bruton’s tyrosine kinase (BTK) inhibitors
